Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994

Cambridge, Mass., Feb. 04, 2019 (Globe Newswire) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced the acceptance by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for SPR994, Spero’s lead product candidate designed to be...This story is related to the following:Pharmaceuticals
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news